Vasodilators and Anti-Oxidant Therapy in Early ATN
Status:
Withdrawn
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Patients developing kidney failure after open heart surgery experience an abrupt decrease in
blood flow to the kidney. The investigators hypothesize that administration of fenoldopam
mesylate (a drug that increases blood flow to the kidney) to patients early in the course of
their disease could reduce progression to dialysis-dependent acute renal failure. The
investigators also hypothesize that restoring blood flow could induce additional injury to
the kidney through the release of reactive oxygen species. Therefore, patients in this
protocol will be randomized to receive a fenoldopam or the anti-oxidant MESNA. The
investigators hypothesize that combination treatment with Fenoldopam and MESNA will decrease
the incidence of death or dialysis at 21 days in patients with early post-operative acute
renal failure.